Belzutifan Synthesis via Enzymatic Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preparing belzutifan, a HIF-2α inhibitor, require the use of hazardous reagents and transition metal catalysts, and involve complex processes that necessitate specialized equipment, making them inefficient and costly for large-scale production.
Innovation Solution
A convergent process for preparing belzutifan that minimizes the use of hazardous reagents and transition metal catalysts, utilizing conventional reactors and involving steps such as contacting hydroxy indanone with a fluorinating agent under acidic conditions, followed by enzyme-catalyzed reductions and subsequent conversions to yield the compound, which can be performed without the need for specialized equipment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If current methods for preparing belzutifan are used, then the compound can be synthesized, but hazardous reagents and transition metal catalysts are required along with specialized equipment
Solution Approach 1:
The patent removes hazardous reagents and transition metal catalysts from the synthetic pathway by employing enzyme-catalyzed reactions. Specifically, it uses a ketoreductase enzyme to replace toxic chemical reducing agents and a fluorinating agent to eliminate the need for hazardous fluorination reagents, thereby extracting harmful elements from the manufacturing process while maintaining synthesis efficiency
Solution Approach 2:
The patent replaces chemical catalysis with biological catalysis. Instead of using transition metal catalysts and hazardous reagents, it employs enzyme catalysts (ketoreductase and fluorinating enzyme) that operate under milder conditions, produce fewer byproducts, and eliminate the need for specialized equipment, thus substituting a mechanical/chemical system with a biological one
2Productivity
If current multi-step synthetic processes are used, then belzutifan can be produced, but capital expenditures for specialized equipment are required
Solution Approach 1:
The patent employs conventional reactor equipment that can be used for multiple purposes in the synthetic pathway. The same type of reactor used for one step can accommodate subsequent enzyme-catalyzed steps, eliminating the need for specialized equipment for each transformation. This universal equipment approach reduces capital expenditures while maintaining the ability to perform large-scale production
Solution Approach 2:
The patent changes the reaction parameters from harsh chemical conditions requiring specialized equipment to mild enzymatic conditions that can be achieved in conventional reactors. By adjusting temperature, pH, and substrate concentration parameters to optimize enzyme activity, the process achieves high productivity using standard equipment, thereby reducing device complexity and capital requirements
3Ease of manufacture
If conventional chemical methods are used, then belzutifan synthesis is achieved, but environmental hazards increase
Solution Approach 1:
The patent converts harmful chemical reactions into beneficial enzymatic processes. The enzyme-catalyzed fluorination and reduction steps replace hazardous chemical transformations, turning potentially harmful reactions into controlled, selective processes that produce fewer byproducts and eliminate toxic waste, thereby converting environmental hazards into benefits
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This process achieves high yields of belzutifan while reducing capital expenditures and environmental hazards, enabling efficient large-scale production suitable for commercial supply and ongoing clinical studies.
Implementation Method 1
contacting the fluoro hydroxyindanone (6) with a ketoreductase comprising an amino acid sequence having at least 90% sequence identify to SEQ ID NO:2 to provide fluorodiol (7)
Implementation Method 2
contacting hydroxy indanone (5) with a fluorinating agent under acidic conditions to yield fluoro hydroxyindanone (6)
Data Source
AI summary
The disclosure provides a novel process and synthetic intermediates for making belzutifan, a HIF-2a inhibitor, useful for the treatment of certain VHL-related indications and cancer.